[go: up one dir, main page]

WO2024084212A1 - Traitement de la fibrose pulmonaire idiopathique avec de l'ensifentrine - Google Patents

Traitement de la fibrose pulmonaire idiopathique avec de l'ensifentrine Download PDF

Info

Publication number
WO2024084212A1
WO2024084212A1 PCT/GB2023/052709 GB2023052709W WO2024084212A1 WO 2024084212 A1 WO2024084212 A1 WO 2024084212A1 GB 2023052709 W GB2023052709 W GB 2023052709W WO 2024084212 A1 WO2024084212 A1 WO 2024084212A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
patient
pulmonary fibrosis
use according
ensifentrine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2023/052709
Other languages
English (en)
Other versions
WO2024084212A8 (fr
Inventor
Tara Renae Rheault
Kathleen RICKARD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verona Pharma Ltd
Original Assignee
Verona Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verona Pharma Ltd filed Critical Verona Pharma Ltd
Priority to CN202380072857.1A priority Critical patent/CN120787157A/zh
Priority to JP2025521209A priority patent/JP2025535129A/ja
Priority to EP23800902.1A priority patent/EP4604962A1/fr
Priority to AU2023362721A priority patent/AU2023362721A1/en
Priority to KR1020257015912A priority patent/KR20250086769A/ko
Publication of WO2024084212A1 publication Critical patent/WO2024084212A1/fr
Anticipated expiration legal-status Critical
Publication of WO2024084212A8 publication Critical patent/WO2024084212A8/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to the treatment of pulmonary fibrosis (PF), and in particular the treatment of idiopathic pulmonary fibrosis (IPF).
  • PF pulmonary fibrosis
  • IPF idiopathic pulmonary fibrosis
  • Ensifentrine (/V-(2- ⁇ (2E)-9,10-dimethoxy-4-oxo-2-[(2,4,6-trimethylphenyl)imino]-6,7- dihydro-2/-/-pyrimido[6,1 -a]isoquinolin-3(4/-/)-yl ⁇ ethyl)urea; also known as RPL554) is a dual PDE3/PDE4 inhibitor (including inhibition of PDE4B) and is described in WO 00/58308 A1 .
  • ensifentrine As a combined phosphodiesterase 3/4 (PDE3/PDE4) inhibitor, ensifentrine has both bronchodilatory and anti-inflammatory activity and is useful in the treatment of respiratory disorders including chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • Pulmonary fibrosis is a disease associated with scarring of the tissue of the lungs. The scarring causes hardening of the lung tissue, which leads to symptoms such as shortness of breath. Pulmonary fibrosis can be caused by a number of factors, including bacterial or viral infection and cigarette smoke. Most pulmonary fibrosis is idiopathic, however, and has no known cause. Idiopathic pulmonary fibrosis (IPF) is a progressive and debilitating disease which affects around five million people globally.
  • ensifentrine may be used to treat pulmonary fibrosis, and in particular idiopathic pulmonary fibrosis, by inhaled administration. Inhaled ensifentrine has also been found to avoid side effects such as diarrhoea.
  • the invention accordingly provides a compound for use in a method of treating idiopathic pulmonary fibrosis in a patient, which compound is ensifentrine or a pharmaceutically acceptable salt thereof, wherein the method comprises administering the compound to the patient by inhalation.
  • Also provided by the invention is a compound for use in a method of treating pulmonary fibrosis in a patient by improving lung function, or by preventing or reducing a reduction in lung function, which compound is ensifentrine or a pharmaceutically acceptable salt thereof, wherein the method comprises administering the compound to the patient by inhalation.
  • the invention further provides a compound for use in a method of treating pulmonary fibrosis in a patient by preventing or reducing fibrosis, which compound is ensifentrine or a pharmaceutically acceptable salt thereof, wherein the method comprises administering the compound to the patient by inhalation.
  • the invention further provides a composition
  • a composition comprising (i) a compound which is ensifentrine or a pharmaceutically acceptable salt and (ii) an anti-fibrotic agent.
  • Figure 1 shows the effect of inhaled ensifentrine on blood IL-6 and IL-8 inflammatory biomarkers.
  • the compound may improve lung function in a patient with pulmonary fibrosis.
  • the compound may increase forced vital capacity (FVC) in a patient with pulmonary fibrosis.
  • FVC forced vital capacity
  • the FVC of the patient one month after the compound is first administered may be at least 0.2%, at least 0.5%, at least 1 % or at least 2% greater than the FVC of the patient on the date the compound is first administered.
  • FVC may be measured by standard spirometry techniques. Typically, as used herein, FVC is determined as set out in the article Standardisation of Spirometry, Eur Resp J 2005; 26; 319-338.
  • the compound may prevent a reduction in lung function in a patient with pulmonary fibrosis.
  • the compound may prevent (or reduce) a reduction in forced vital capacity (FVC) in a patient with pulmonary fibrosis.
  • FVC forced vital capacity
  • the FVC of the patient one month after the compound is first administered may be no more than 0.2%, no more than 0.5%, no more than 1 % or no more than 2% less than the FVC of the patient on the date the compound is first administered.
  • the compound may act as an anti-fibrotic. As such, the compound may prevent or reduce fibrosis, and in particular the compound may prevent or reduce fibrosis of lung tissue. The compound may therefore prevent formation of fibrosis or scarring of lung tissue in a patient or the compound may reduce the amount of fibrosis or scar tissue in the lungs of the patient. The compound may improve lung function by preventing or reducing fibrosis of lung tissue.
  • the compound may be for use in a method of treating pulmonary fibrosis in a patient by preventing or reducing fibrosis.
  • the method may comprise treating pulmonary fibrosis in a patient by reducing fibrosis in the lungs of the patient.
  • the compound may cause a reduction in TGF-[3 concentration in the patient, for instance a reduction in lung TGF-[3 concentration in the patient.
  • the pulmonary fibrosis may be caused by infection or an external chemical irritant.
  • the pulmonary fibrosis may be fibrosing alveolitis, for instance cryptogenic fibrosing alveolitis.
  • the pulmonary fibrosis is preferably idiopathic pulmonary fibrosis.
  • Fibrosis of the lungs associated with pulmonary fibrosis in a patient may be measured by determining a decline in lung function of the patient.
  • the decline in lung function may be a decline in forced vital capacity (FVC) of the patient.
  • FVC forced vital capacity
  • the compound may prevent a decline in FVC of the patient by preventing fibrosis of lung tissue.
  • the compound may improve FVC of the patient by reducing fibrosis of lung tissue.
  • the FVC of the patient may increase following administration of the compound. For instance, the FVC of the patient may be increased by at least 10 mL or at least 20 mL one month after the first inhaled administration of the compound (compared with FVC at the first administration of the compound). The FVC of the patient may decrease by no more than 30 mL or no more than 50 mL one month after the first inhaled administration of the compound (compared with FVC at the first administration of the compound).
  • the compound may decrease the frequency and/or severity of pulmonary fibrosis (PF) exacerbations in the patient.
  • the compound may decrease the frequency of PF exacerbations.
  • the patient may suffer two or fewer (for instance one or zero) PF exacerbations per year while being treated with the compound, for instance as a maintenance therapy.
  • the number of PF exacerbations experienced by the patient per year during treatment with the compound may be one to three fewer than the number of PF exacerbations experienced by the patient per year prior to treatment with the compound.
  • the compound may increase the time to a first PF exacerbation in the patient. Accordingly, the patient may not have yet experienced a COPD exacerbation and the compound may increase the time until the patient experiences a first PF exacerbation (i.e. the first PF exacerbation is delayed).
  • the compound may accordingly reduce the risk of PF exacerbations in a patient suffering from pulmonary fibrosis.
  • the patient has suffered one or more PF exacerbations in the year preceding first administration of the compound. For instance, the patient may have suffered two or more PF exacerbations in the year preceding first administration of the compound. The patient may for instance have suffered from at least one severe PF exacerbation (i.e. requiring hospital treatment) in the preceding year.
  • the patient may have suffered one or more PF exacerbations in the six months preceding first administration of the compound, or one or more PF exacerbations in the one month preceding first administration of the compound.
  • the PF exacerbation may be an acute PF exacerbation.
  • the PF exacerbation may be an acute exacerbation of IPF (AE-IPF).
  • AE-IPF is defined as a sudden acceleration of the disease or an idiopathic acute injury superimposed on the diseased lung that leads to a significant decline in lung function.
  • the patient may be suffering from idiopathic pulmonary fibrosis (IPF) and the compound may decrease the frequency and/or seventy of acute exacerbation of IPF (AE-IPF) in the patient.
  • IPF idiopathic pulmonary fibrosis
  • AE-IPF seventy of acute exacerbation of IPF
  • the patient may be male.
  • the patient may be female.
  • the patient may have an age of greater than or equal to 65 years.
  • the patient may have an age of less than 65 years.
  • the patient may be taking a background medication selected from one or more of an anti-fibrotic agent, a long-acting muscarinic antagonist (LAMA), a long- acting beta-agonist (LABA) and an inhaled corticosteroid (ICS).
  • LAMA long-acting muscarinic antagonist
  • LAA long-acting beta-agonist
  • ICS inhaled corticosteroid
  • the patient may not be taking a background medication which is a muscarinic antagonist or a beta-agonist.
  • the compound is ensifentrine or a pharmaceutically acceptable salt thereof.
  • Pharmaceutically acceptable salts are well known to the skilled person.
  • the compound is ensifentrine (i.e. ensifentrine free base).
  • the method comprises administering the compound to the patient by inhalation.
  • a pharmaceutical composition comprising the compound and one or more pharmaceutically acceptable excipients or diluents is typically administered to the patient by inhalation, for instance by nebuliser, pressurised metered dose inhaler (pMDI) or dry powder inhaler (DPI).
  • pMDI pressurised metered dose inhaler
  • DPI dry powder inhaler
  • the method comprises administering the compound to the patient by inhalation from a nebuliser.
  • Nebulisers aerosolise a liquid pharmaceutical composition into an aerosol that is inhaled into a patient's respiratory tract.
  • nebulisers include a soft mist nebuliser, a vibrating mesh nebuliser, a jet nebuliser and an ultrasonic wave nebuliser.
  • Suitable nebuliser devices include the Philips l-nebTM (Philips), the Philips SideStream (Philips), the AeroNeb® (Philips), the Philips InnoSpire Go (Philips), the Pari LC Sprint (Pari GmbH), the AERxRTM Pulmonary Delivery System (Aradigm Corp) and the Pari LC Plus Reusable Nebuliser (Pari GmbH).
  • the nebulizer may for instance be a PARI LC Sprint jet nebulizer with a PARI Vios® PRO Aerosol Delivery System PARI BOY® compressor.
  • the compound may be inhaled via the nebuliser for from 1 to 15 minutes.
  • the method comprises administering the compound to the patient once, twice or three times per day, for instance twice or three times per day.
  • the compound may be administered to the patient by inhalation once, twice or three times a day.
  • the method comprises administering the compound to the patient by inhalation twice a day.
  • the method may comprise administering a first dose of the compound in the morning (for instance within 3 hours following waking) and a second dose of the compound in the evening (for instance within 3 hours before bed).
  • the morning and evening doses are administered from 10 to 14 hours apart, for instance about 12 hours apart.
  • the compound may be used in any suitable therapeutically effective amount.
  • the daily dose of the compound is from 0.1 to 40 mg or from 0.1 to 20 mg.
  • the method comprises administering a total daily dose of the compound of from 0.5 to 10 mg.
  • the total daily dose of the compound e.g. ensifentrine free base
  • the total daily dose of the compound is from 5 to 7 mg, for instance about 6 mg per day.
  • the term “about” may represent a variation of ⁇ 10% of the stated value.
  • the total daily dose of the compound may be 6.0 mg.
  • the compound is administered twice a day in two separate doses which are the same or similar.
  • the method may comprise administering the compound to the patient twice a day in a first dose of from 1 to 10 mg and a second dose of from 1 to 10 mg.
  • the method may comprise administering the compound to the patient twice a day in a first dose of from 1 to 5 mg and a second dose of from 1 to 5 mg.
  • the method may comprise administering the compound to the patient twice a day in a first dose of from 2 to 4 mg and a second dose of from 2 to 4 mg.
  • the method may comprise administering two doses of about 2 mg, about 3 mg, about 4 mg, about 5 mg or about 6 mg ensifentrine free base to the patient per day by inhalation.
  • the method comprises administering two doses of about 3 mg ensifentrine free base to the patient per day by inhalation.
  • the method preferably comprises administering a dose of about 3 mg of the compound to the patient twice a day (3 mg BID) by inhalation. More preferably, the method comprises administering by nebuliser a dose of about 3 mg the compound to the patient twice a day. Each dose may be 3.0 mg free base ensifentrine administered by nebulizer.
  • the method comprises administering the compound to the patient at least once per day for at least 8 weeks.
  • the compound may be administered to the patient at least once per day for at least 16 weeks, preferably for at least 24 weeks.
  • the compound may be administered daily to the patient for at least 1 year.
  • the method may comprise administering the compound to the patient at least once every 24 hours, preferably at least twice every 24 hours, for at least 8 weeks, preferably for at least 16 weeks, more preferably for at least 24 weeks.
  • the compound is typically used as a maintenance therapy.
  • the compound is preferably administered as a suspension formulation, i.e. a suspension of particles comprising the compound in a diluent.
  • the compound may alternatively be delivered as a dry powder, for instance a dry powder comprising particles comprising the compound and particles of a carrier such as lactose.
  • the method typically comprises administering an inhalable pharmaceutical composition comprising a suspension of particles of the compound in a diluent.
  • the particles comprising the compound typically have a particle size distribution with a Dv50 of from 0.5 pm to 5.0 pm.
  • the particles preferably have a Dv50 of from 1 .0 pm to 2.0 pm.
  • Particle sizes are described herein by reference to the Dv50 value, which is the median particle size for a volume distribution. Thus, half the volume of the particles have diameters of less than the Dv50 value and half the volume of the particles have diameters of greater than the Dv50 value. This is a well-known manner in which to describe particle size distributions.
  • the technique used to measure the Dv50 values as stated herein is typically laser diffraction.
  • the particle size distribution of the particles comprising the compound may be as measured by laser diffraction using a wet powder dispersion system.
  • the particle size distribution can be measured by laser diffraction using a Malvern Spraytec in conjunction with a wet dispersion cell.
  • the instrument parameters for the Malvern Spraytec are as follows:
  • the particles comprising the compound typically comprise ensifentrine (i.e. ensifentrine free base).
  • the particles may comprise at least 90 wt% ensifentrine free base relative to the total weight of the particles.
  • the particles may comprise at least 99 wt% ensifentrine.
  • the particles may consist of ensifentrine.
  • the concentration of particles comprising the compound in the inhalable pharmaceutical composition is typically from 0.1 to 5.0 mg/mL, preferably from 0.1 to 2.5 mg/mL, more preferably from 1 .0 to 2.0 mg/mL.
  • the inhalable pharmaceutical composition typically further comprises one or more tonicity adjusters, one or more buffers and one or more surfactants.
  • the tonicity adjuster is typically sodium chloride.
  • buffers include a citrate buffer, a phosphate buffer, an acetate buffer, and a bicarbonate buffer.
  • the buffer is a phosphate buffer, for instance sodium dihydrogen phosphate dihydrate and/or disodium phosphate dihydrate.
  • surfactants include lecithin, oleic acid, polyoxyethylene glycol alkyl ethers (for instance PEG 300, PEG 600, PEG 1000, Brij 30, Brij 35, Brij 56, Brij 76 and Brij 97), polypropylene glycol (for instance PPG 2000), glucoside alkyl ethers, polyoxyethylene glycol octylphenol ethers, polyoxyethylene glycol alkylphenol ethers, glycerol alkyl esters, polyoxyethylene glycol sorbitan alkyl esters (polysorbates, for instance polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80), sorbitan alkyl esters (for instance sorbitan monolaurate (Span 20), sorbitan monooleate (Span 80) and sorbitan trioleate (Span 85)), cocamide MEA, cocamide DEA, dodecyldimethylamine oxide, block copolymers of polyethylene glycol and polypropylene
  • the one or more surfactants comprise a polysorbate and/or a sorbitan alkyl ester.
  • the one or more surfactants may for instance comprise polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate) or polysorbate 80 (polyoxyethylene (20) sorbitan monooleate).
  • the one or more surfactants may for instance comprise sorbitan monolaurate (Span 20), sorbitan monooleate (Span 80) or sorbitan trioleate (Span 85).
  • the sterile liquid vehicle comprises polysorbate 20 and/or sorbitan monolaurate (Span 20).
  • the method may comprise administering to the patient an inhalable liquid pharmaceutical composition comprising:
  • the inhalable liquid pharmaceutical composition may comprise:
  • particles consisting of ensifentrine free base at a concentration of from 0.5 to 6 mg/mL;
  • a side effect of some anti-fibrotic treatments is gastrointestinal adverse events such as diarrhoea. These side effects can prevent patients from taking the compound, and may reduce patient compliance. This is particularly the case for patients already suffering from, or susceptible to, gastrointestinal disorders such as diarrhoea.
  • the compound may be used to treat pulmonary fibrosis in a patient suffering from, or susceptible to a gastrointestinal disorder.
  • the patient may be susceptible to, or suffering from, diarrhoea.
  • the patient may be suffering from ulcerative colitis, Crohn's disease, microscopic colitis, celiac disease, irritable bowel syndrome, bile acid malabsorption, or diverticulitis.
  • the compound may be used in combination with a second active agent.
  • the compound may be administered separately or simultaneously with the second active agent.
  • the patient may already be taking a second active agent as a background therapy for pulmonary fibrosis.
  • treatment with the second active agent may start at around the same time as treatment with the compound.
  • the compound and the second active agent may be administered in a fixed combination.
  • the second active agent is typically an anti-fibrotic agent, a muscarinic receptor antagonist, a beta-adrenergic receptor agonist or an inhaled corticosteroid.
  • the compound may accordingly be used in combination with an anti-fibrotic agent, a muscarinic receptor antagonist, a beta-adrenergic receptor agonist or an inhaled corticosteroid.
  • the second active agent is anti-fibrotic agent.
  • the anti-fibrotic agent may be pirfenidone, nintedanib or a pharmaceutically acceptable salt thereof.
  • the anti-fibrotic agent is pirfenidone.
  • the second active agent may be administered by inhalation or orally.
  • the anti-fibrotic agent is administered orally.
  • the patient may be taking an oral anti-fibrotic agent such as pirfenidone as a background medication.
  • the second active agent may be a long-acting muscarinic receptor antagonist (LAMA), a long-acting beta-adrenergic receptor agonist (LABA) or an inhaled corticosteroid.
  • LAMAs include aclidinium, darotropium, tiotropium, glycopyrrolate, umeclidinium and pharmaceutically acceptable salts thereof.
  • LABAs include salmeterol, formoterol, indacaterol, vilanterol, olodaterol, abediterol, carmoterol and pharmaceutically acceptable salts thereof.
  • inhaled corticosteroids include beclomethosone, budesonide, fluticasone propionate, ciclesonide, mometasone, fluticasone furoate and pharmaceutically acceptable salts thereof.
  • the compound may alternatively be used as a monotherapy.
  • the compound may be for use in treating pulmonary fibrosis (e.g. idiopathic pulmonary fibrosis) as the sole active agent.
  • the compound is not administered in combination with a muscarinic receptor antagonist or a beta- adrenergic receptor agonist.
  • ensifentrine may be used in combination with an anti-fibrotic agent.
  • the invention accordingly also provides a composition comprising (i) a compound which is ensifentrine or a pharmaceutically acceptable salt and (ii) an anti-fibrotic agent.
  • the composition is typically a pharmaceutical composition.
  • the composition may further comprise one or more pharmaceutically acceptable carriers, diluents or excipients.
  • the one or more pharmaceutically acceptable carriers, diluents or excipients may be as defined herein.
  • the composition may be administered as described herein. For instance, the composition may be administered by inhalation.
  • the two active ingredients may be in fixed or free combination. Typically, the two active ingredients are in fixed combination. For instance, they may be intermixed. The two active ingredients may be present in an inhalable liquid pharmaceutical composition.
  • the anti-fibrotic agent is pirfenidone, nintedanib or a pharmaceutically acceptable salt thereof.
  • the anti-fibrotic agent is preferably pirfenidone.
  • composition may be for use in a method for treating or preventing pulmonary fibrosis as defined herein.
  • the invention also provides an anti-fibrotic agent (for instance pirfenidone) for use in a method of treating pulmonary fibrosis in a patient in combination with a compound which is ensifentrine or a pharmaceutically acceptable salt thereof.
  • an anti-fibrotic agent for instance pirfenidone
  • the method may be as further defined herein.
  • the invention also provides a method of preventing or treating pulmonary fibrosis in a patient by improving lung function, or by preventing or reducing a reduction in lung function, which method comprises administering by inhalation a therapeutically effective amount of a compound which is ensifentrine or a pharmaceutically acceptable salt thereof to the patient.
  • a compound which is ensifentrine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for a method of treating pulmonary fibrosis by improving lung function, or by preventing or reducing a reduction in lung function, wherein the method comprises administering the compound to the patient by inhalation.
  • the invention also provides a method of treating IPF in a patient, which method comprises administering by inhalation a therapeutically effective amount of a compound which is ensifentrine or a pharmaceutically acceptable salt thereof to the patient.
  • a compound which is ensifentrine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for a method of treating IPF, wherein the method comprises administering the compound to the patient by inhalation.
  • the study population included patients aged 40-80 years with moderate to severe COPD (FEVi 30% - 70% p.n., FEVi/forced vital capacity (FVC) ratio ⁇ 0.7, with mMRC > 2).
  • the randomization stratified (a) the use of stable background maintenance LAMA or LABA therapy use (approx. 50%. yes or no) and (b) cigarette smoking (current or former). Inhaled corticosteroid (ICS) maintenance therapy was permitted in up to 20% of patients under certain provisions.
  • the investigational product and placebo were provided in 2.5 mL unit dose format in an ampule and administered via a nebuliser.
  • the formulation of the investigational product (ensifentrine suspension formulation) and placebo are shown in Table 1 below.
  • the anti-fibrotic activity of ensifentrine is assessed using a rodent model of bleomycin-induced lung fibrosis.
  • Bleomycin is administered to anaesthetised rodents to induce lung fibrosis. Ensifentrine is then administered to the test rodents by inhalation for a period, and the rodents are subsequently killed. Lung samples are obtained for histological studies to determine fibrotic area.
  • Ensifentrine is determined to have an anti-fibrotic effect in bleomycin-induced lung fibrosis.
  • Example 3 effect of ensifentrine on bleomycin-induced pulmonary fibrosis
  • Rats were administered bleomycin to induce pulmonary fibrosis. After a week, they then received a daily inhaled dosage of ensifentrine or a control over a period of two weeks. At the end of the two weeks, the rats were sacrificed and their airways were analysed for Bronchoalveolar lavage (BAL) differential cell counts and TGF-[3 concentration.
  • BAL Bronchoalveolar lavage
  • TGF-[3 is a key cytokine in the development of tissue fibrosis. Macrophages and other immune cells produce TGF-[3, which induces the differentiation of fibroblasts to myofibroblasts and increases TGF-[3 expression. Overexpression of active TGF-[31 in the lungs of rodents causes severe and progressive tissue fibrosis, including fibroblastic foci and honeycomb formation. Inhibiting TGF-[31 may be central to the anti-fibrotic effect of a drug.
  • the rats were subjected to an intratracheal challenge of either 0.9 % w/v saline or bleomycin, the latter used to induce pulmonary fibrosis.
  • Control 1 subjected 12 rats from the saline challenge group to daily administration of the vehicle suspension article via inhalation for the full 21 days.
  • Control 2 subjected 12 rats from the bleomycin challenge group to daily administration of the vehicle suspension article via inhalation for the full 21 days.
  • Table 2 The experimental set-up is summarised in Table 2 below.
  • the BAL differential cell counts at day 21 showed a reduction in total inflammatory cell and macrophage infiltration into the rat airways following treatment with ensifentrine at 3 mg/kg/day (Experiment 1 ) and 10 mg/kg/day (Experiment 2), in comparison to the bleomycin Control 2.
  • the TGF-[3 concentration at day 21 was also lower in the rats following ensifentrine treatment compared to those of the bleomycin Control 2.
  • TGF-[3 concentration in the rat lungs following treatment with ensifentrine was lower than the TGF-[3 concentration following treatment with nintedanib (Experiment 3).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un composé destiné à être utilisé dans une méthode de traitement de la fibrose pulmonaire idiopathique chez un patient, lequel composé est l'ensifentrine ou un sel pharmaceutiquement acceptable de celui-ci, la méthode comprenant l'administration du composé au patient par inhalation. La présente invention concerne un composé destiné à être utilisé dans une méthode de traitement de la fibrose pulmonaire chez un patient par amélioration de la fonction pulmonaire, ou par prévention ou atténuation d'une réduction de la fonction pulmonaire, lequel composé est l'ensifentrine ou un sel pharmaceutiquement acceptable de celui-ci, la méthode comprenant l'administration du composé au patient par inhalation.
PCT/GB2023/052709 2022-10-20 2023-10-19 Traitement de la fibrose pulmonaire idiopathique avec de l'ensifentrine Ceased WO2024084212A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN202380072857.1A CN120787157A (zh) 2022-10-20 2023-10-19 使用恩塞芬汀治疗特发性肺纤维化
JP2025521209A JP2025535129A (ja) 2022-10-20 2023-10-19 エンシフェントリンでの特発性肺線維症の治療
EP23800902.1A EP4604962A1 (fr) 2022-10-20 2023-10-19 Traitement de la fibrose pulmonaire idiopathique avec de l'ensifentrine
AU2023362721A AU2023362721A1 (en) 2022-10-20 2023-10-19 Treatment of idiopathic pulmonary fibrosis with ensifentrine
KR1020257015912A KR20250086769A (ko) 2022-10-20 2023-10-19 엔시펜트린을 이용한 특발성 폐섬유증 치료

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263417762P 2022-10-20 2022-10-20
US63/417,762 2022-10-20
US202363580726P 2023-09-06 2023-09-06
US63/580,726 2023-09-06

Publications (2)

Publication Number Publication Date
WO2024084212A1 true WO2024084212A1 (fr) 2024-04-25
WO2024084212A8 WO2024084212A8 (fr) 2025-05-08

Family

ID=88695385

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2023/052709 Ceased WO2024084212A1 (fr) 2022-10-20 2023-10-19 Traitement de la fibrose pulmonaire idiopathique avec de l'ensifentrine

Country Status (6)

Country Link
EP (1) EP4604962A1 (fr)
JP (1) JP2025535129A (fr)
KR (1) KR20250086769A (fr)
CN (1) CN120787157A (fr)
AU (1) AU2023362721A1 (fr)
WO (1) WO2024084212A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition
US12409180B2 (en) 2022-02-21 2025-09-09 Verona Pharma Plc Formulation production process

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058308A1 (fr) 1999-03-31 2000-10-05 Vernalis Limited Derives de pyrimido [6,1-a] isoquinolein-4-one et leur utilisation en medecine
US20160000790A1 (en) * 2013-03-15 2016-01-07 Verona Pharma Plc Drug combination
US20190282565A1 (en) * 2018-03-19 2019-09-19 Gui-Bai Liang Methods and Compositions for Treating Idiopathic Pulmonary Fibrosis
US20220265549A1 (en) * 2019-08-12 2022-08-25 Verona Pharma Plc Pharmaceutical composition comprising ensifentrine

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000058308A1 (fr) 1999-03-31 2000-10-05 Vernalis Limited Derives de pyrimido [6,1-a] isoquinolein-4-one et leur utilisation en medecine
US20160000790A1 (en) * 2013-03-15 2016-01-07 Verona Pharma Plc Drug combination
US20190282565A1 (en) * 2018-03-19 2019-09-19 Gui-Bai Liang Methods and Compositions for Treating Idiopathic Pulmonary Fibrosis
US20220265549A1 (en) * 2019-08-12 2022-08-25 Verona Pharma Plc Pharmaceutical composition comprising ensifentrine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Standardisation of Spirometry", EUR RESP J, vol. 26, 2005, pages 319 - 338
HERRMANN FRANZISKA ELENA ET AL: "BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis", FRONTIERS IN PHARMACOLOGY, vol. 13, 1 January 2022 (2022-01-01), CH, pages 838449 - 838449, XP055924739, ISSN: 1663-9812, DOI: 10.3389/fphar.2022.838449 *
LUIGINO CALZETTA ET AL: "Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways", PULMONARY PHARMACOLOGY & THERAPEUTICS, vol. 32, 1 January 2015 (2015-01-01), pages 15 - 23, XP055791247 *
MARIO CAZZOLA ET AL: "Ensifentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease", PHARMACEUTICAL PATENT ANALYST, vol. 7, no. 6, 1 November 2018 (2018-11-01), GB, pages 249 - 257, XP055651020, ISSN: 2046-8954, DOI: 10.4155/ppa-2018-0030 *
TOBY MAHER ET AL: "Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib", DRUG DESIGN, DEVELOPMENT AND THERAPY, 1 June 2013 (2013-06-01), pages 503, XP055125113, ISSN: 1177-8881, DOI: 10.2147/DDDT.S38833 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12409180B2 (en) 2022-02-21 2025-09-09 Verona Pharma Plc Formulation production process
US12194045B1 (en) 2023-06-26 2025-01-14 Verona Pharma Plc Particulate composition
US12251384B1 (en) 2023-06-26 2025-03-18 Verona Pharma Plc Particulate composition

Also Published As

Publication number Publication date
EP4604962A1 (fr) 2025-08-27
CN120787157A (zh) 2025-10-14
AU2023362721A1 (en) 2025-04-17
JP2025535129A (ja) 2025-10-22
KR20250086769A (ko) 2025-06-13
WO2024084212A8 (fr) 2025-05-08

Similar Documents

Publication Publication Date Title
US20240165055A1 (en) Treatment
EP1452179A1 (fr) Nouveau combination d'un puissant agoniste beta 2 de longue duree et un corticosteroid
WO2019142214A1 (fr) Composition pharmaceutique comprenant du tiotropium destinée à être inhalée
WO2024084212A1 (fr) Traitement de la fibrose pulmonaire idiopathique avec de l'ensifentrine
US9737520B2 (en) Aclidinium for use in improving the quality of sleep in respiratory patients
KR20170003601A (ko) Ｃｏｐｄ의 치료를 위한 티오트로피움 브로마이드, 포르모테롤 및 부데소니드의 조합
KR20250040090A (ko) 액상 약제학적 조성물
US20240382489A1 (en) Liquid pharmaceutical composition
ZA200503308B (en) New synergistic combination comprising roflumilast and formoterol
US20060199865A1 (en) Synergistic combination comprising roflumilast and (r,r) - formoterol
WO2025093848A1 (fr) Ensifentrine pour le traitement de la bronchectasie
WO2025168546A1 (fr) Ensifentrine pour le traitement de la bpco
TWI905086B (zh) 包含雷芬那新（ｒｅｖｅｆｅｎａｃｉｎ）之醫藥組合物用於治療慢性阻塞性肺疾病之用途及選擇治療用之吸入遞送裝置之方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23800902

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: AU2023362721

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2025521209

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025521209

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 202380072857.1

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2023362721

Country of ref document: AU

Date of ref document: 20231019

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20257015912

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2023800902

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023800902

Country of ref document: EP

Effective date: 20250520

WWP Wipo information: published in national office

Ref document number: 1020257015912

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2023800902

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 202380072857.1

Country of ref document: CN